Patent: 10,799,473

Summary for Patent: 10,799,473

Title:	Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
Abstract:	Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade. Also provided is a composition for use in reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation, the composition comprising a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade.
Inventor(s):	Day; Regina M (Rockville, MD), Panganiban; Ronald-Allan M (Bethesda, MD)
Assignee:	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (Bethesda, MD)
Application Number:	14/771,171
Patent Claims:	see list of patent claims

Details for Patent 10,799,473

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	March 25, 2003		2034-03-03
Pharmacia & Upjohn Company Llc	SOMAVERT	pegvisomant	For Injection	021106	July 31, 2014		2034-03-03